Literature DB >> 17922743

Relative blood volume measurements during hemodialysis: comparisons between three noninvasive devices.

Judith J Dasselaar1, Roel M Huisman, Paul E DE Jong, Casper F M Franssen.   

Abstract

The monitoring of relative blood volume changes (DeltaRBV) has been advocated for the prevention of hemodialysis (HD) hypotension. Stand-alone devices (Crit-Line) or devices incorporated into the HD apparatus (blood volume monitor [BVM], Hemoscan) are widely used for this purpose. Comparisons between devices are scarce. The aim of this study was, first, to compare DeltaRBV results from these 3 devices with DeltaRBV calculated from changes in laboratory-derived hemoglobin (DeltaRBV-lab-Hb) and, second, to compare DeltaRBV results between the different devices. Fourteen patients received 2 HD treatments in a randomized order: one with the Hemoscan and Crit-Line combination and one with the BVM and Crit-Line combination. DeltaRBV-lab-Hb was measured at 2 and 4 hr into the HD session. Bland-Altman analyses showed that DeltaRBV results from the 3 devices differed systematically from DeltaRBV-lab-Hb, i.e., the difference between the 3 devices and DeltaRBV-lab-Hb varied significantly (p<0.05) with the magnitude of the measurement. The interdevice comparison showed considerable differences in DeltaRBV results. At the end of the treatment, a significant difference (p<0.05) between DeltaRBV measured by the Hemoscan and Crit-Line device (-9.8+/-2.7% and -11.5+/-4%, respectively) was found. In most patients, a systematic difference between Crit-Line and Hemoscan and between Crit-Line and BVM was observed. Relative blood volume change measurements by Crit-Line, Hemoscan, and BVM yield results that differ systematically from the results obtained from laboratory-derived Hb changes. Furthermore, there are substantial differences in DeltaRBV results between the 3 DeltaRBV devices.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17922743     DOI: 10.1111/j.1542-4758.2007.00216.x

Source DB:  PubMed          Journal:  Hemodial Int        ISSN: 1492-7535            Impact factor:   1.812


  7 in total

1.  Model predictive control of relative blood volume and heart rate during hemodialysis.

Authors:  Faizan Javed; Andrey V Savkin; Gregory S H Chan; Paul M Middleton; Philip Malouf; Elizabeth Steel; James Mackie; Teddy M Cheng
Journal:  Med Biol Eng Comput       Date:  2010-02-11       Impact factor: 2.602

2.  The relative trending accuracy of noninvasive continuous hemoglobin monitoring during hemodialysis in critically ill patients.

Authors:  Hiroshi Yamada; Minako Saeki; Junko Ito; Kazuhiro Kawada; Aya Higurashi; Hiromi Funakoshi; Kohji Takeda
Journal:  J Clin Monit Comput       Date:  2014-05-03       Impact factor: 2.502

3.  Randomized Crossover Trial of Blood Volume Monitoring-Guided Ultrafiltration Biofeedback to Reduce Intradialytic Hypotensive Episodes with Hemodialysis.

Authors:  Kelvin C W Leung; Robert R Quinn; Pietro Ravani; Henry Duff; Jennifer M MacRae
Journal:  Clin J Am Soc Nephrol       Date:  2017-10-10       Impact factor: 8.237

Review 4.  Focused Real-Time Ultrasonography for Nephrologists.

Authors:  Matthew J Kaptein; Elaine M Kaptein
Journal:  Int J Nephrol       Date:  2017-02-02

5.  Hemodialysis-induced changes in hematocrit, hemoglobin and total protein: Implications for relative blood volume monitoring.

Authors:  Leszek Pstras; Malgorzata Debowska; Alicja Wojcik-Zaluska; Wojciech Zaluska; Jacek Waniewski
Journal:  PLoS One       Date:  2019-08-12       Impact factor: 3.240

6.  Design and construct an optical device to determine relative blood volume in patients undergoing hemodialysis.

Authors:  Banafshe Dormanesh; Shahnaz Tofangchiha; Vahid Abouei; Hani Sharifian
Journal:  Iran Red Crescent Med J       Date:  2014-04-05       Impact factor: 0.611

7.  Ultrafiltration biofeedback guided by blood volume monitoring to reduce intradialytic hypotensive episodes in hemodialysis: study protocol for a randomized controlled trial.

Authors:  Kelvin C W Leung; Robert R Quinn; Pietro Ravani; Jennifer M MacRae
Journal:  Trials       Date:  2014-12-10       Impact factor: 2.279

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.